Purpose: The purpose of this study was to characterize reductions in intraocular pressure (IOP) and the need for IOP-lowering medications following phacoemulsification combined with Kahook Dual Blade-assisted goniosynechialysis and excisional goniotomy in eyes with angle-closure glaucoma and cataract.
Methods: In this retrospective, interventional case series, preoperative, operative, and postoperative data were collected through 6 months of follow-up from 42 eyes of 24 subjects. Outcomes included mean IOP reduction, reduction in IOP-lowering medications, and the proportion of patients achieving IOP reduction ≥20%, IOP≤18 mm Hg, and reduction of ≥1 medication.
Results: Preoperatively, mean (SE) IOP was 25.5 (0.7) mm Hg and the mean number of IOP-lowering medications used was 2.3 (0.1) per eye. Through 6 months of follow-up, mean IOP reductions of 10.1 to 12.8 mm Hg (38.4% to 49.5%; P<0.0001) and mean IOP medication reductions of -2.2 to -2.3 (91.7% to 98.4%; P<0.0001) were seen. At month 6, 92.9% of eyes (39/42) achieved IOP≤18 mm Hg, 100% (42/42) achieved IOP reduction of ≥20%, 100% (42/42) required ≥1 fewer medications for IOP control, and 85.7% (36/42) were medication free.
Conclusions: Phacoemulsification combined with Kahook Dual Blade-assisted goniosynechialysis and excisional goniotomy safely provides statistically and clinically meaningful reductions in both IOP and the need for IOP-lowering medications in eyes with angle-closure glaucoma.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/IJG.0000000000001256 | DOI Listing |
BMC Ophthalmol
December 2024
Department 3, 15-20 National Vision Hospital, IHU FOReSIGHT, 28 rue de Charenton, Paris, 75012, France.
Background: The EyeCee ONE intraocular lens (Nidek, Gamagori, Japan) has been withdrawn from the market due to a high number of reports of severe ocular hypertension (OHT) following phacoemulsification with implantation of this intraocular lens (IOL). In this case series, we report the results of a toxicological analysis and the surgical management of five patients with severe OHT following the implantation of defective EyeCee ONE IOLs during cataract surgery.
Cases Presentation: Five patients developed early, severe OHT refractory to maximal medical therapy following uneventful phacoemulsification (PCE) cataract surgery with implantation of an EyeCee ONE IOL from a defective lot.
J Clin Med
December 2024
Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, 3010 Bern, Switzerland.
: This study aimed to investigate the five-year outcomes of deep sclerectomy (DS) in patients with pseudoexfoliation glaucoma (PEXG) and primary open-angle glaucoma (POAG). : This retrospective, observational, unicentric study analyzed POAG and PEXG patients. Intraocular pressure (IOP), the number of IOP-lowering medications, peripapillary retinal nerve fiber layer (RNFL) thickness, the number of postoperative interventions, surgical success rates, and secondary surgery rates were evaluated at baseline and during follow-up appointments.
View Article and Find Full Text PDFOphthalmol Ther
December 2024
University Eye Clinic Maastricht, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands.
Introduction: To investigate 5-year outcomes on intraocular pressure (IOP) and safety of micropulse transscleral cyclophotocoagulation (TSCPC) in patients with glaucoma.
Methods: Patients with mild to advanced glaucoma who underwent a standardized micropulse TSCPC procedure at the University Eye Clinic Maastricht from November 2016 to February 2019 were included.
Results: A total of 165 eyes were included, with outcomes for 112 eyes available after 5-year follow-up.
Cureus
November 2024
Department of Ophthalmology, George Washington University School of Medicine and Health Sciences, Washington, D.C., USA.
Purpose: To evaluate the effectiveness of selective laser trabeculoplasty (SLT) in reducing intraocular pressure (IOP) and medication use in treated and untreated eyes of angle recession glaucoma (ARG) patients within a year post procedure.
Methods: A retrospective chart review was conducted on nine ARG patients treated with SLT at George Washington University between January 1, 2008, and January 1, 2022. Patients were excluded if they had no ARG diagnosis, did not undergo SLT, lacked follow-up within one year after SLT, or had undergone laser or glaucoma surgery in the treated or untreated eye within 12 months before SLT.
Cureus
November 2024
Medical Affairs, Sun Pharma Laboratories Limited, Mumbai, IND.
Introduction Fixed-dose combinations (FDCs) have the potential in glaucoma management to improve efficacy due to the complementary mechanism of action of the drugs as well as compliance while reducing adverse effects by minimizing exposure to preservatives and the financial burden on the patients. FDC of brinzolamide/timolol has demonstrated efficacy and safety in multinational phase 3 studies in primary open-angle glaucoma (POAG) and ocular hypertension. However, efficacy and safety in the Indian population are not known.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!